Cardio Diagnostics to Present AI-Powered Cardiovascular Risk Tools at Four National Benefits Conferences

Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD(TM), PrecisionCHD(TM) and the HeartRisk(TM) population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.

The conferences represent a strategic opportunity for Cardio Diagnostics to demonstrate how its precision medicine solutions can transform cardiovascular disease prevention and management. Cardiovascular disease remains the leading cause of death globally and a significant financial burden for employers. According to the Centers for Disease Control and Prevention, heart disease costs the United States about $363 billion each year in health care services, medications, and lost productivity. By leveraging artificial intelligence and genetic-epigenetic analysis, Cardio Diagnostics aims to shift the paradigm from reactive treatment to proactive prevention.

Cardio Diagnostics' platform utilizes a proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine to deliver personalized risk assessments. The Epi+Gen CHD test evaluates coronary heart disease risk by combining genetic and epigenetic markers, while PrecisionCHD offers a more comprehensive analysis. The HeartRisk population insights platform provides employers and health plans with aggregated data to identify high-risk groups and tailor interventions. These tools are designed to integrate seamlessly into existing wellness programs, offering actionable insights without requiring extensive lifestyle changes from participants.

The company's participation in these conferences underscores its commitment to addressing the root causes of rising healthcare costs. By identifying individuals at elevated risk before symptoms appear, Cardio Diagnostics enables early intervention through lifestyle modifications, medication, or closer monitoring. This proactive approach not only improves patient outcomes but also reduces the financial strain on health plans and employers. For benefits decision-makers, the ability to stratify risk across a population allows for more efficient allocation of resources and targeted wellness initiatives.

Cardio Diagnostics, based in Los Angeles, is at the forefront of precision cardiovascular medicine. The company's innovative approach has garnered attention from investors and industry experts, as evidenced by its listing on NASDAQ under the ticker CDIO. For more information about Cardio Diagnostics and its product offerings, visit the company's newsroom at https://ibn.fm/CDIO. The full press release detailing the conference schedule and product demonstrations is available at https://ibn.fm/qFRHu.